Precision Medicine in Oncology®

Girish Putcha, MD, PhD, discusses the results of the AI EMERGE trial (NCT03688906) in colorectal cancer.

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

Aditya Bardia, MD, MPH, discusses the clinical utility of liquid biopsies in breast cancer.

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

Girish Putcha, MD, PhD, chief medical officer and clinical laboratory director, Freenome, discusses blood-based detection of early-stage colorectal cancer (CRC) using multiomics and machine learning.

Despite a reasonable expectation that expression of HER3 and its ligand heregulin would be predictive biomarkers for HER3-targeted therapy, their usefulness in clinical trials has been hit-and-miss. Nevertheless, investigators have persevered, and new types of drugs have largely supplanted the first generation in clinical trials.

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the utility of liquid biopsies in lung cancer.

Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

Although PD-L1 expression is the most established yardstick of response to immune checkpoint immunotherapy, its clinical utility as a biomarker remains an enigma further complicated by the variety of assays and algorithms for measuring it.

Justin F. Gainor, MD, discusses a neoadjuvant use of biomarkers in nonmetastatic lung cancer.

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Recent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.